A study on the effect of hemostatic agent and Kampo medicine (goreisan) for the clinical course of chronic subdural hematoma

Abstract

In my personal experience, carbazochrome sodium sulfonate hydrate (Adona) and goreisan (TJ–17) had been used widely for the prevention to chronic sub­dural hematoma (cSDH) after minor head trauma, and the postoperative recurrence prevention. In this report, I tested the preventive effect to the reoperation of cSDH by using carbazochrome sodium sulfonate hydrate (Adona) and goreisan （TJ–17） in the recent decade. A total of 64 patients were included in this study. There were 43 males and 21 females, with an average age of 76.5 years. Eleven patients used antiplatelet agents, and 7 patients used warfarin potassium (Warfarin) before surgery. Only 2 patients needed the second surgery. There was no adverse effect by using carbazochrome sodium sulfonate hydrate (Adona) and goreisan (TJ–17). Average duration of carbazochrome sodium sul­fonate hydrate (Adona) and goreisan (TJ–17) usage was 60.1 days. Carbazochrome sodium sulfonate hydrate (Adona) and goreisan （TJ–17） therapy after the cSDH surgery has low reoperative rate (3.1%) and it has enough sufficient effect.